2019 annual financial data
Halozyme Therapeutics 2019 Operating margin
Direct answer
Operating margin was -34.5%.
Operating income was -67,610,000 USD and net income was -72,240,000 USD.
Operating cash flow was -85,423,000 USD.
Get free Halozyme Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 195,992,000 USD
- Operating income
- -67,610,000 USD
- Net income
- -72,240,000 USD
- Operating cash flow
- -85,423,000 USD